TSHA

In the past six months, Taysha reported its first-quarter 2026 financial results, including a net loss of $42.4 million, but reaffirmed FDA alignment on a BLA pathway for TSHA-102 and stated that its cash resources are expected to fund planned operating expenses into 2028. The company presented preclinical data at ASGCT, demonstrating that TSHA-102's scAAV9 construct delivers approximately 30-fold higher MeCP2 expression compared to ssAAV9. Taysha reported full-year 2025 financial results, highlighting significant execution in 2025, including dosing multiple Rett syndrome patients in the REVEAL pivotal trial and FDA clearance to initiate the ASPIRE trial. News related to options trading was reported in February and November 2026. Chardan Capital and Citizens maintained positive recommendations for Taysha Gene Therapies, and Fintel reported an increase in Taysha Gene Therapies' price target. The FDA granted Breakthrough Therapy designation to TSHA-102 for Rett syndrome and finalized alignment on the REVEAL pivotal trial protocol.